Though skin cancer incidence is low, liver transplant recipients may still benefit from long-term dermatological surveillance to help monitor malignancies and infections, according to a recent Singapore study.
The humanized anti-CD20 monoclonal antibody rituximab was superior to mycophenolate mofetil (MMF) in terms of producing sustained complete remission* (CR) and a glucocorticoid-sparing effect in patients with moderate-to-severe pemphigus vulgaris, the PEMPHIX study has shown.
Both tetracycline treatment and clindamycin–rifampicin combination therapy demonstrate significant efficacy after 12 weeks in patients with hidradenitis suppurativa (HS), reports a study. Regardless of disease severity, efficacy does not substantially differ between the two treatments.
New drug applications approved by US FDA as of 16-31 July 2021 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Patients with psoriasis taking the immunosuppressant methotrexate had low antibody responses to SARS-CoV-2 after receiving the first dose of Pfizer-BioNTech’s BNT162b2 vaccine but had shown T-cell responses, according to a study that was the first to look at T-cell responses in patients taking methotrexate.
Bimekizumab appeared to be more effective than secukinumab in improving skin clearance in patients with moderate-to-severe plaque psoriasis, according to the multinational, phase IIIb BE RADIANT trial presented at AAD 2021.
The increasing use of social media and online reviews has made it easier for patients to comment publicly—on Facebook and Google reviews, for instance—on the care they receive. Positive comments are heartening for any healthcare professional to read.
The oral Janus kinase inhibitor upadacitinib – which has gained approval for the treatment of rheumatoid arthritis (RA) – showed potential for treating individuals with psoriatic arthritis (PsA) who have insufficient response to nonbiologic disease-modifying antirheumatic drugs, according to the phase III SELECT-PsA 1 trial.